Seglentis is a drug owned by Kowa Pharmaceuticals America Inc. It is protected by 7 US drug patents filed from 2021 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 03, 2031. Details of Seglentis's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10238668 | Co-crystals of tramadol and coxibis |
Apr, 2030
(4 years from now) | Active |
| US10245276 | Co-crystals of tramadol and coxibs |
Apr, 2030
(4 years from now) | Active |
| US8598152 | Co-crystals of tramadol and coxibs |
Apr, 2030
(4 years from now) | Active |
| US9012440 | Co-crystals of tramadol and coxibs |
Apr, 2030
(4 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8846744 | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
Jun, 2031
(5 years from now) | Active |
| US11478488 | Co-crystals of tramadol and coxibs |
Apr, 2030
(4 years from now) | Active |
| US10548909 | Co-crystals of tramadol and coxibs |
Apr, 2030
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Seglentis's patents.
Latest Legal Activities on Seglentis's Patents
Given below is the list of recent legal activities going on the following patents of Seglentis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10238668 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8598152 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US9012440 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10548909 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8846744 |
| Notice of Final Determination- Ineligible | 06 Jun, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10238668 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10548909 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US8598152 |
FDA has granted several exclusivities to Seglentis. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Seglentis, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Seglentis.
Exclusivity Information
Seglentis holds 1 exclusivities. All of its exclusivities have expired in 2024. Details of Seglentis's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2024 |
US patents provide insights into the exclusivity only within the United States, but
Seglentis is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Seglentis's family patents as well as insights into
ongoing legal events
on those patents.
Seglentis's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Seglentis's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 03, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Seglentis Generics:
There are no approved generic versions for Seglentis as of now.
About Seglentis
Seglentis is a drug owned by Kowa Pharmaceuticals America Inc. It is used for managing pain in adults. Seglentis uses Celecoxib; Tramadol Hydrochloride as an active ingredient. Seglentis was launched by Kowa Pharms in 2021.
Approval Date:
Seglentis was approved by FDA for market use on 15 October, 2021.
Active Ingredient:
Seglentis uses Celecoxib; Tramadol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Celecoxib; Tramadol Hydrochloride ingredient
Treatment:
Seglentis is used for managing pain in adults.
Dosage:
Seglentis is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 56MG;44MG | TABLET | Discontinued | ORAL |